<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00178178</url>
  </required_header>
  <id_info>
    <org_study_id>Pain Catheter Study</org_study_id>
    <nct_id>NCT00178178</nct_id>
  </id_info>
  <brief_title>Arthroscopic Anterior Cruciate Ligament Reconstruction: A Comparison of Three Catheter Placement Positions</brief_title>
  <official_title>A Placebo Controlled, Prospective, Randomized Clinical Investigation of the Efficacy of Continuous Infusion Regional Anesthetic on Postoperative Pain Following Arthroscopic Anterior Cruciate Ligament Reconstruction: A Comparison of Three Catheter Placement Positions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Rochester</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>BREG, Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Rochester</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This investigation will evaluate the subjective effect on postoperative pain of three
      catheter placements in the knee:

        1. intraarticular infusion only,

        2. patellar tendon harvest site only,

        3. both intraarticular and patellar tendon harvest site.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There will be 96 subjects recruited into this study. Based on power analysis for repeated
      measures analysis of variance, the sample size required for this investigation is 24 subjects
      per group based on a 90% confidence interval and alpha of 0.05. There will be 24 subjects in
      Group 1 (intraarticular bupivicaine infusion only). There will be 24 subjects in Group 2
      (patellar tendon harvest site only with bupivicaine). There will be 24 subjects in Group 3
      (both intraarticular and patellar tendon harvest site with bupivicaine). There will be 24
      subjects in the control, Group 4 (intraarticular infusion physiologic saline only). All
      patients will be recruited under the discretion of the principal investigator.

      The primary outcome measure for this investigation will be the Postoperative Patient Diary.
      This document records patient's subjective evaluations of pain, comfort, ability to sleep,
      activity level and quality of life. The Postoperative Patient Diary will be administered
      daily on the day of surgery and each morning and each evening before the patient retires for
      3 postoperative days. All pain medications taken during the 3 days of the postoperative
      evaluation will be recorded on the Postoperative Patient Diary.

      The investigational treatment for this investigation is the use of a Pain Care 3000
      continuous infusion regional anesthesia device and accepted pharmacologic modalities for the
      control of postoperative pain with continuous infusion of a local anesthetic agent
      (bupivicaine 0.5%) intraarticularly only (Group 1), at the patellar tendon harvest site
      (Group 2) and combined continuous infusion at the patellar tendon harvest site and
      intraarticular infusion (Group 3).

      Patients randomly assigned to the control group (Group 4) will receive intraarticular
      infusion physiologic saline only.

      The catheter delivers 2 cc of bupivicaine 0.5% per hour total. In patients in Group 3, with 2
      catheters (1 in the patellar tendon harvest site and 1 intraarticular infusion), the
      catheters are connected by a &quot;Y&quot; connector. The dosage of bupivicaine will be split among the
      two sites.

      The device does not allow delivery of more than 2 cc per hour. The patient cannot adjust or
      alter the flow rate.

      A standard general anesthetic protocol will be employed at the discretion of the supervising
      anesthesiologist.

      Prior to surgery, all patients will be instructed on both the use of the continuous infusion
      device and on the methods for completing the study questionnaires. Catheters will be placed
      at the end of the surgical procedure according to the randomization schedule. Patients will
      then complete the study questionnaires on the day of surgery and on three consecutive days
      following surgery.

      The clinical evaluation will last 3 postoperative days. During the postoperative period,
      sufficient additional pain medications will be available to all patients to sufficiently
      control postoperative pain.

      No analgesics or local anesthetics, other than those specified should be taken during the
      postoperative period by any subject. Other medications such as &quot;rescue analgesics&quot; considered
      to be necessary to the patient's welfare will be given at the discretion of the principal
      investigator. If the medication provided is for pain relief, the patient must request it. The
      administration of all medication, from premedication until discharge from the hospital, must
      be recorded in the patient diary if it has a direct bearing on the study outcome. Any
      medication taken for pain following hospital discharge within the established post discharge
      follow up period must be recorded in the patient diary.

      The investigator is responsible for assuring that there are procedures and expertise
      available to cope with medical emergencies that may occur during the study. In case of
      emergency, symptomatic treatment will be provided according to hospital routine. The reason
      for the emergency may constitute a serious adverse event.

      After surgery, a patient would be discontinued from the study if it is discovered that they
      show a previously unrecognized allergy to the medication (bupivicaine). This would be rare.
      If it occurs, the catheter would be immediately removed, thus ending the infusion of the
      medication and the patient would no longer participate in the study.

      Standard of Care Procedures:

      Opioid based analgesics or their derivatives have been the standard of care in managing
      postoperative pain for this procedure. These medications have been administered orally,
      intramuscularly, or intravenously. There is no difference in the surgical procedure except
      for the insertion of the catheter at the surgical site upon closure of the surgical wound.
      All patients will receive Toradol 30 mg parenterally q6h x2, followed by Toradol 10 mg PO QID
      for 3 days. This anti-inflammatory has an analgesic effect and is not used prn. Any narcotic
      is used only as needed and the use of this will be tracked for this study.

      All patients (including those in the study) will be kept in the hospital overnight following
      surgery and will receive a patient controlled analgesia (PCA) device for intravenous
      administration of morphine through the night of the hospital stay. Morphine usage during this
      period will be recorded.

      Patients undergoing this knee surgery are admitted to the 23 hour unit, stay overnight, and
      are discharged the following morning usually before 10:00 am. This is the standard of care
      and will be the same for those participating in the study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2005</start_date>
  <completion_date type="Actual">November 2007</completion_date>
  <primary_completion_date type="Actual">November 2007</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain</measure>
    <time_frame>3 day</time_frame>
    <description>Pain over the first three days post-operatively. This will be identified by the use of the Postoperative Patient Diary. This document records patient's subjective evaluations of pain, comfort, ability to sleep, activity administered daily on the day of surgery and each morning and each evening before the patient retires for 3 postoperative days. All pain medications taken during the 3 days of the postoperative evaluation will be recorded on the Postoperative Patient Diary.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">96</enrollment>
  <condition>Pain, Postoperative</condition>
  <arm_group>
    <arm_group_label>Drug: Bupivicaine 0.5% Intraaticulary Only</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Breg Pain Care 3000 Catheter;Bupivicaine 0.5%;Intraaticular Only
Continuous infusion of a local anesthetic agent (bupivicaine 0.5%) intraarticularly only via Breg Pain Care 3000 Catheter</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Drug: Bupivicaine 0.5% Patellar Tendon Site</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Breg Pain Care 3000 Catheter;Bupivicaine 0.5%;Patellar Tendon Site Only
Continuous infusion of a local anesthetic agent (bupivicaine 0.5%) at the patellar tendon harvest site via Breg Pain Care 3000 Catheter</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Drug: Bupivicaine 0.5% Intraarticular and Patellar Tendon</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Breg Pain Care 3000 Catheter;Bupivicaine 0.5%; Intraarticular and Patellar Tendon Sites
Continuous infusion of a local anesthetic agent (bupivicaine 0.5%) at the Patellar Tendon Harvest Site and Intraarticular infusion via Breg Pain Care 3000 Catheter</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Drug: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Breg Pain Care 3000 Catheter with Placebo
Receive liquid with no pain medication (placebo) through a catheter in one part of the operative knee via Breg Pain Care 3000 Catheter</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Breg Pain Care 3000 Catheter</intervention_name>
    <description>Device: Breg Pain Care 3000 Catheter</description>
    <arm_group_label>Drug: Bupivicaine 0.5% Intraaticulary Only</arm_group_label>
    <arm_group_label>Drug: Bupivicaine 0.5% Patellar Tendon Site</arm_group_label>
    <arm_group_label>Drug: Bupivicaine 0.5% Intraarticular and Patellar Tendon</arm_group_label>
    <arm_group_label>Drug: Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivicaine 0.5%</intervention_name>
    <description>Drug: Bupivicaine 0.5 %</description>
    <arm_group_label>Drug: Bupivicaine 0.5% Intraaticulary Only</arm_group_label>
    <arm_group_label>Drug: Bupivicaine 0.5% Patellar Tendon Site</arm_group_label>
    <arm_group_label>Drug: Bupivicaine 0.5% Intraarticular and Patellar Tendon</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Drug: Placebo</description>
    <arm_group_label>Drug: Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject symptoms

               1. Daily pain

               2. Pain restricts work, recreation and/or activities of daily living (ADL)

          -  Cognitive function sufficient to understand protocol and to complete subject diary or
             other analysis tools employed.

          -  Must read, write, and understand the English language.

          -  American Society of Anesthesiologists (ASA) risk 1 or 2

          -  Gender - Both

          -  Age 15 - 65 years (parental consent will be obtained on all subjects under age 18).

          -  Provided written informed consent

        Exclusion Criteria:

          -  Neuropathic joint

          -  Remote source of ongoing sepsis

          -  Severe vascular disease

          -  Any medical condition precluding safe anesthesia, surgery, or rehabilitation

          -  Comorbid conditions preventing full functional activity or which require continuous
             use of pain medication.

          -  A known history of allergy, sensitivity, or any other form of reaction to local
             anesthetics of the amide type, acetaminophen, or opioids.

          -  Suspected inability to comply with study procedures, including language difficulties
             or medical history and/or concomitant disease, as judged by the investigator.

          -  A neurological and/or vascular condition which may affect the outcome of the
             procedure.

          -  Receiving regular treatment with analgesics, sedatives, or any other medication with
             central nervous system effects.

          -  Tendency to bleed

          -  Women who are pregnant or are not practicing medically acceptable contraception (a
             pregnancy test is used pre-operatively as part of standard of care).

          -  Participation in other clinical studies during this study or in the 14 days prior to
             admission to this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert D Bronstein, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Rochester</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Strong Memorial Hospital</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2005</study_first_posted>
  <results_first_submitted>April 9, 2015</results_first_submitted>
  <results_first_submitted_qc>April 30, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 18, 2015</results_first_posted>
  <last_update_submitted>August 27, 2015</last_update_submitted>
  <last_update_submitted_qc>August 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 11, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>anterior cruciate ligament reconstruction</keyword>
  <keyword>Pain Care 3000</keyword>
  <keyword>Catheter Placement</keyword>
  <keyword>Pain</keyword>
  <keyword>Breg, Inc</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Anesthetics</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Intraarticulary Only</title>
          <description>Continuous infusion of a local anesthetic agent (bupivicaine 0.5%) intraarticularly only via Breg Pain Care 3000 Catheter
Breg Pain Care 3000 Catheter: Pump that is designed to deliver local anesthetic directly to surgical site for several days.</description>
        </group>
        <group group_id="P2">
          <title>Patellar Tendon Harvest Site Only</title>
          <description>Continuous infusion of a local anesthetic agent (bupivicaine 0.5%) at the patellar tendon harvest site via Breg Pain Care 3000 Catheter
Breg Pain Care 3000 Catheter: Pump that is designed to deliver local anesthetic directly to surgical site for several days.</description>
        </group>
        <group group_id="P3">
          <title>Patellar Tendon Harvest Site and Intraarticular</title>
          <description>Continuous infusion of a local anesthetic agent (bupivicaine 0.5%) at the Patellar Tendon Harvest Site and Intraarticular infusion via Breg Pain Care 3000 Catheter
Breg Pain Care 3000 Catheter: Pump that is designed to deliver local anesthetic directly to surgical site for several days.</description>
        </group>
        <group group_id="P4">
          <title>Placebo</title>
          <description>Receive liquid with no pain medication (placebo) through a catheter in one part of the operative knee via Breg Pain Care 3000 Catheter
Breg Pain Care 3000 Catheter: Pump that is designed to deliver local anesthetic directly to surgical site for several days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="24"/>
                <participants group_id="P4" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="24"/>
                <participants group_id="P4" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Drug: Intraarticularly Only</title>
          <description>Continuous infusion of a local anesthetic agent (bupivicaine 0.5%) intraarticularly only via Breg Pain Care 3000 Catheter
Breg Pain Care 3000 Catheter: Pump that is designed to deliver local anesthetic directly to surgical site for several days.</description>
        </group>
        <group group_id="B2">
          <title>Drug: Patellar Tendon Harvest Site Only</title>
          <description>Continuous infusion of a local anesthetic agent (bupivicaine 0.5%) at the patellar tendon harvest site via Breg Pain Care 3000 Catheter
Breg Pain Care 3000 Catheter: Pump that is designed to deliver local anesthetic directly to surgical site for several days.</description>
        </group>
        <group group_id="B3">
          <title>Drug: Patellar Tendon Harvest Site and Intraarticular</title>
          <description>Continuous infusion of a local anesthetic agent (bupivicaine 0.5%) at the Patellar Tendon Harvest Site and Intraarticular infusion via Breg Pain Care 3000 Catheter
Breg Pain Care 3000 Catheter: Pump that is designed to deliver local anesthetic directly to surgical site for several days.</description>
        </group>
        <group group_id="B4">
          <title>Placebo Comparator</title>
          <description>Receive liquid with no pain medication (placebo) through a catheter in one part of the operative knee via Breg Pain Care 3000 Catheter
Breg Pain Care 3000 Catheter: Pump that is designed to deliver local anesthetic directly to surgical site for several days.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
            <count group_id="B2" value="24"/>
            <count group_id="B3" value="24"/>
            <count group_id="B4" value="24"/>
            <count group_id="B5" value="96"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="20"/>
                    <measurement group_id="B5" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="20"/>
                    <measurement group_id="B5" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="24"/>
                    <measurement group_id="B5" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="21"/>
                    <measurement group_id="B5" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="24"/>
                    <measurement group_id="B5" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pain</title>
        <description>Pain over the first three days post-operatively. This will be identified by the use of the Postoperative Patient Diary. This document records patient's subjective evaluations of pain, comfort, ability to sleep, activity administered daily on the day of surgery and each morning and each evening before the patient retires for 3 postoperative days. All pain medications taken during the 3 days of the postoperative evaluation will be recorded on the Postoperative Patient Diary.</description>
        <time_frame>3 day</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intraarticulary Only</title>
            <description>Continuous infusion of a local anesthetic agent (bupivicaine 0.5%) intraarticularly only via Breg Pain Care 3000 Catheter
Breg Pain Care 3000 Catheter: Pump that is designed to deliver local anesthetic directly to surgical site for several days.</description>
          </group>
          <group group_id="O2">
            <title>Patellar Tendon Harvest Site Only</title>
            <description>Continuous infusion of a local anesthetic agent (bupivicaine 0.5%) at the patellar tendon harvest site via Breg Pain Care 3000 Catheter
Breg Pain Care 3000 Catheter: Pump that is designed to deliver local anesthetic directly to surgical site for several days.</description>
          </group>
          <group group_id="O3">
            <title>Patellar Tendon Harvest Site and Intraarticular</title>
            <description>Continuous infusion of a local anesthetic agent (bupivicaine 0.5%) at the Patellar Tendon Harvest Site and Intraarticular infusion via Breg Pain Care 3000 Catheter
Breg Pain Care 3000 Catheter: Pump that is designed to deliver local anesthetic directly to surgical site for several days.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Receive liquid with no pain medication (placebo) through a catheter in one part of the operative knee via Breg Pain Care 3000 Catheter
Breg Pain Care 3000 Catheter: Pump that is designed to deliver local anesthetic directly to surgical site for several days.</description>
          </group>
        </group_list>
        <measure>
          <title>Pain</title>
          <description>Pain over the first three days post-operatively. This will be identified by the use of the Postoperative Patient Diary. This document records patient's subjective evaluations of pain, comfort, ability to sleep, activity administered daily on the day of surgery and each morning and each evening before the patient retires for 3 postoperative days. All pain medications taken during the 3 days of the postoperative evaluation will be recorded on the Postoperative Patient Diary.</description>
          <units>participants that experienced pain</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="24"/>
                    <measurement group_id="O4" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Intraartciularly Only</title>
          <description>Continuous infusion of a local anesthetic agent (bupivicaine 0.5%) intraarticularly only via Breg Pain Care 3000 Catheter
Breg Pain Care 3000 Catheter: Pump that is designed to deliver local anesthetic directly to surgical site for several days.</description>
        </group>
        <group group_id="E2">
          <title>Patellar Tendon Harvest Site Only</title>
          <description>Continuous infusion of a local anesthetic agent (bupivicaine 0.5%) at the patellar tendon harvest site via Breg Pain Care 3000 Catheter
Breg Pain Care 3000 Catheter: Pump that is designed to deliver local anesthetic directly to surgical site for several days.</description>
        </group>
        <group group_id="E3">
          <title>Patellar Tendon Harvest Site and Intraarticular</title>
          <description>Continuous infusion of a local anesthetic agent (bupivicaine 0.5%) at the Patellar Tendon Harvest Site and Intraarticular infusion via Breg Pain Care 3000 Catheter
Breg Pain Care 3000 Catheter: Pump that is designed to deliver local anesthetic directly to surgical site for several days.</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>Receive liquid with no pain medication (placebo) through a catheter in one part of the operative knee via Breg Pain Care 3000 Catheter
Breg Pain Care 3000 Catheter: Pump that is designed to deliver local anesthetic directly to surgical site for several days.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Robert Bronstein</name_or_title>
      <organization>University of Rochester</organization>
      <phone>585-275-1024</phone>
      <email>robert_bronstein@urmc.rochester.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

